A different mechanism — immune-regulatory, not the HPA axis. A measurable biomarker. A two-week onset, measured in a 60-person randomized, placebo-controlled trial. Give your practice something new to offer — and something you can verify with bloodwork.
Study design: Randomized, double-blind, placebo-controlled (parallel). N=60. 8-week intervention, 1 mg/day. Population: healthy adults, ages 18–65. Sponsor: Kioga Inc. with the University of Colorado Boulder. Registered NCT07604038.
Active ingredient: NeuroAlly™ (KGA-10™), a heat-killed postbiotic of Mycolicibacterium petrae. 1 mg/day oral capsule.
Primary endpoints:
Secondary endpoints:
Mechanism category (academic literature): The published M. vaccae literature (Stanford and colleagues at UCL; Lowry and colleagues at CU Boulder) describes the organism as engaging immune-regulatory pathways, distinct from the hormonal (HPA/cortisol) or neurological (NMDA) pathways targeted by adaptogens and nootropics. This positions KGA-10™ in a novel mechanistic category by lineage. The supporting literature is preclinical and animal-model; the clinical evidence on īther's product effects rests on the 2026 RCT of NeuroAlly™.
Key differentiators vs. comparators:
Data from a 60-person randomized, double-blind, placebo-controlled clinical trial in healthy adults, 2026 (NCT07604038). Full topline available on request; peer-reviewed publication pending.
We review practitioner applications within 48 hours. Qualified clinics receive wholesale access and a complimentary 30-day personal supply.
Application received. We'll reply within 48 hours with wholesale access and your complimentary 30-day supply.
We respond within 48 hours. No spam. No sales calls.